---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000068"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:52.078382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders

## Summary
- Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.
- Cash and cash equivalents $690.2M at June 30, 2025, up from $559.9M at Dec 31, 2024.
- Board approved return of $375M excess capital to stockholders; cash runway into H1 2028.
- Lead asset KER-065 progressing toward Phase 2 trial in Duchenne muscular dystrophy starting Q1 2026.
- R&D expenses $43.5M, G&A $14.5M for Q2 2025; both increased vs year-ago period.

## SEC filing metadata
- accession: 0001664710-25-000068
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/0001664710-25-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/kros-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000068
- JSON: https://secwatch.observer/filing/0001664710-25-000068.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.